COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Sensor Augmented Pump Therapy Versus Multiple Daily Injection Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01921322
Recruitment Status : Completed
First Posted : August 13, 2013
Results First Posted : July 6, 2017
Last Update Posted : July 6, 2017
Information provided by (Responsible Party):
Medtronic Diabetes

Brief Summary:
This is a prospective, randomized (open label), multi-center and post-market study. The study is to compare effectiveness of sensor-augmented pump (SAP) therapy versus multiple daily injection (MDI) therapy in hospitalized patients with insulin treating type 2 diabetes in China

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Device: Pump Other: CGMS Gold Not Applicable

Detailed Description:

Primary objective:

To compare the length of time to achieve target glucose range using Self-Monitoring Blood Glucose (SMBG), as reference method, with the 722 Paradigm Real-Time insulin pump versus MDI

Secondary Objectives:

To compare glycemic variability (using CGM as reference method) with the 722 Paradigm Real-Time insulin pump versus MDI

This is a prospective, randomized (open label), multi-center study. The clinical study staff will conduct screening tests according to inclusion/exclusion criteria in order to verify the subject's eligibility for the study.

Inpatient Period A patient is admitted into hospital for treatment of diabetes


Subjects are randomized (at a 1:1 ratio) to group A or B in the study database. A total of 80 subjects will be randomized into 2 study groups:

  • Group A will wear 722 Paradigm Real-Time System (treated with 24h per day insulin infusion)
  • Group B will be on MDI and wear the CGMS-Gold (treated with 4 insulin injections).

It is anticipated that the total duration for the study will be within one year from site initiation to finalization of all data entry and monitoring.

Each subject will participate in the study approximately 2 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 118 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Subjects randomly assigned to undergo treatment using either the Paradigm 722 insulin pump or multiple daily insulin injections.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Sensor Augmented Pump Therapy Versus Multiple Daily Injection Therapy for Hospitalized Patients in China With Type 2 Diabetes; Time to Target
Study Start Date : April 2013
Actual Primary Completion Date : May 2015
Actual Study Completion Date : May 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Pump
Paradigm 722 insulin pump used for insulin infusion and continuous glucose monitoring
Device: Pump
722 Paradigm Real-Time System

Active Comparator: MDI
Multiple daily insulin injections used for treatment
Other: CGMS Gold
Device used to collect retrospective sensor data, blinded to the subjects, to compare to the treatment arm

Primary Outcome Measures :
  1. Time to Target [ Time Frame: Up to 14 days in hospital ]
    length of time to achieve target glucose range using Self-Monitoring Blood Glucose (SMBG), as reference method, with the 722 Paradigm Real-Time insulin pump versus Multiple Daily Injection

Secondary Outcome Measures :
  1. Glycemic Variability [ Time Frame: Up to 14 days in hospital ]
    Glycemic variability (mean amplitude glycemic excursion) using CGM as reference method

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subject is 18 to 65 years old at time of screening
  2. A clinical diagnosis of type 2 diabetes > 6 months prior to the screening as determined by the Investigator,
  3. Treating with insulin at least one injection per day prior to participate in the study
  4. Glycosylated hemoglobin (A1C) > 8% at screening
  5. Subject needs to be hospitalized to receive treatment for glucose management according to Endocrinologists' discretion
  6. Subject is willing to follow protocol and underdo all study procedures
  7. Subject is willing and able to provide informed written consent personally or by legal proxy

Exclusion Criteria:

  1. Subject has known hypersensitivity to insulin or insulin infusion set
  2. Subject has been treated with drugs with a known effect on BG within 8 weeks before enrollment other than diabetes medications such as insulin or oral agents.
  3. random blood glucose is above 33 mmol/L
  4. Subject is currently using real time CGM therapy prior to screening
  5. Subject is currently using insulin pump therapy prior to screening
  6. Female subject who is pregnant, or plans to become pregnant during the course of the study
  7. Patients who are critically ill that must go to intensive critical care unit per Investigator discretion
  8. Subject has any systemic disease or medical condition found on the screening tests that may interfere with the safety of the patient and efficacy of the study treatment, in the opinion of the Investigator, may preclude him/her from participating in the study. The following includes, but not limited to, those conditions:

    • Female subject has a positive serum pregnancy screening test
    • Subject has visually impaired or disability limits the use of RT-CGM.
    • Subject has any unresolved adverse skin condition in the area of sensor placement or device replacement (e.g., psoriasis, rash, Staphylococcus infection)
    • Subject has disease with a known effect on BG such as Active Graves' disease
    • Subject has a history of alcohol abuse
  9. Any other condition, which may not be suitable for the study at physician's discretion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01921322

Layout table for location information
China, Jilin
The Second Hospital of Jilin University
Changchun, Jilin, China
Chinese PLA General Hospital
Beijing, China
Sponsors and Collaborators
Medtronic Diabetes
Layout table for additonal information
Responsible Party: Medtronic Diabetes Identifier: NCT01921322    
Other Study ID Numbers: CEP270
First Posted: August 13, 2013    Key Record Dates
Results First Posted: July 6, 2017
Last Update Posted: July 6, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases